# Jesús G. Berdeja

Source: https://onco.cc/people/jesus-berdeja/  
OnCo record `jesus-berdeja` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval.

## Summary

Jesús Berdeja (Sarah Cannon Research Institute, Nashville) was principal investigator and first author of CARTITUDE-1, the pivotal trial showing the BCMA CAR-T ciltacabtagene autoleucel produces responses in 98% of heavily pretreated myeloma patients with median progression-free survival near three years, the deepest responses seen in relapsed myeloma. He runs a large community-based early-phase programme.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; car-t; community-research
- Role: Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute
- Specialisms: Multiple myeloma; CAR T-cell therapy; Early drug development; Community-based trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- institutions: [Tennessee Oncology / Greco-Hainsworth Centers for Research](https://onco.cc/institutions/tennessee-oncology/)
- trials: [CARTITUDE-1](https://onco.cc/trials/cartitude-1/)
- key papers: [CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/)

---
JSON: https://onco.cc/api/v1/entities/jesus-berdeja.json